...
首页> 外文期刊>AIDS Research and Human Retroviruses >Medium-Term Probability of Success of Antiretroviral Treatment after Early Warning Signs of Treatment Failure in West African Adults
【24h】

Medium-Term Probability of Success of Antiretroviral Treatment after Early Warning Signs of Treatment Failure in West African Adults

机译:西非成年人治疗失败的早期预警信号后,抗逆转录病毒治疗成功的中期可能性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

West African adults with warning signs of failure of antiretroviral treatment (ART) at 6 months were assessed for the probability and factors associated with success at 36 months. After 6 months on ART, patients were included if they had a bad immunologic response (BIR) (month 6 CD4 count300copies/ml), or both (Dual). They were followed for 30 months after inclusion. CD4 counts and HIV-1 RNA were measured every 3 months. We estimated the probability of reaching immunovirologic success (CD4 count >350/mm3 and plasma HIV-1 RNA 90% between month 6 and month 36 had a likelihood of success 3.8 and 3.6 higher than other patients. The 36-month probability of success was 0.56 and 0.86 in patients with an MPR 90% and 0.59 and 0.84 in patients with and without resistance. After warning signs of failure at 6 months, a large proportion of patients reaches immunovirologic success before 36 months provided there is a high rate of adherence to medication and the absence of early resistance mutations.
机译:评估了在6个月时有抗逆转录病毒治疗(ART)失败警告迹象的西非成年人在36个月时与成功相关的可能性和因素。接受ART治疗6个月后,如果患者的免疫反应不良(BIR)(6个月CD4计数300拷贝/ ml)或两者均存在(双重),则将其包括在内。入组后随访30个月。每3个月测量一次CD4计数和HIV-1 RNA。我们估计了获得免疫病毒学成功的可能性(CD4计数> 350 / mm 3 ),并且在6个月至36个月之间血浆HIV-1 RNA 90%的成功率比其他患者高3.8和3.6。 MPR为90%的患者,其36个月的成功概率为0.56和0.86,有耐药和无耐药的患者,其36个月的成功概率为0.59和0.84,在6个月出现失败的警告信号后,大部分患者在提供36个月的免疫病毒学之前获得成功对药物的依从性很高,并且没有早期耐药性突变。

著录项

  • 来源
    《AIDS Research and Human Retroviruses》 |2009年第8期|783-793|共11页
  • 作者单位

    INSERM U897, Université Victor Segalen Bordeaux 2, Bordeaux, France.;

    INSERM U897, Université Victor Segalen Bordeaux 2, Bordeaux, France.;

    CeDReS Laboratory, CHU de Treichville, Abidjan, C?te d'Ivoire.;

    Service de Virologie, CHU Necker-Enfants, Paris, France.;

    CeDReS Laboratory, CHU de Treichville, Abidjan, C?te d'Ivoire.;

    Programme PACCI, CHU de Treichville, Abidjan, C?te d'Ivoire.;

    Programme PACCI, CHU de Treichville, Abidjan, C?te d'Ivoire.;

    Service des Maladies Infectieuses et Tropicales, CHU de Treichville, Abidjan, C?te d'Ivoire.;

    INSERM U897, Université Victor Segalen Bordeaux 2, Bordeaux, France.;

    Service des Maladies Infectieuses et Tropicales, CHU de Treichville, Abidjan, C?te d'Ivoire.;

    INSERM U897, Université Victor Segalen Bordeaux 2, Bordeaux, France.;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号